MediWound (MDWD) said Wednesday it has initiated a global phase III trial evaluating EscharEx for the treatment of venous leg ulcers.
The trial will assess the efficacy and safety of EscharEx across 40 sites in the US and Europe, enrolling 216 patients in a randomized, double-blind study, focusing on complete debridement and wound closure, MediWound said.
Patients will undergo up to eight daily applications over two weeks, followed by ten weeks of wound management, the company said, adding that an interim analysis is planned for mid-2026 after 65% of patients have completed treatment.
To support the trial, MediWound said it has partnered with Solventum (SOLV), Molnlycke, and MiMedx Group (MDXG), who will supply advanced products to standardize wound management and enhance patient outcomes across all study sites.
MediWound also said it plans to start a phase II study comparing EscharEx to collagenase in VLU patients in 2025 and a phase II/III trial for diabetic foot ulcers in 2026.
MDWD shares were 1.7% higher in recent trading.
Price: 17.56, Change: +0.30, Percent Change: +1.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.